Human cell programming company bit.bio closes $25M Series D
bit.bio's Series D round, which includes participation from existing investor M&G Investments and Abcam founder Jonathan Milner, will support expansion of its human cell model portfolio and broader technology access. The company's proprietary opti-ox platform enables consistent, scalable production of defined human cell types to overcome donor variability and supply limitations. The ioCells portfolio includes over 50 human cell types designed for drug discovery and safety testing, addressing the shift away from traditional animal models toward human cell-based alternatives.
Key points
- Series D funding of $25 million from M&G Investments and industry leaders
- opti-ox platform produces defined human cell types at scale
- Reduces reliance on animal models and addresses donor variability in research
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. Tech.eu did the reporting; read the original for the full story.
Read the full story at Tech.eu
